Zhenpeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhenpeng Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Mei Zhang
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication- Mei Zhang
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Yan Tang
Department of Clinical Laboratory, Deyang People's Hospital, Deyang, Sichuan province, China
1 shared publication - Yin Liu
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication - Yuping Zeng
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication Zhenpeng Wang
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Vol. 57 (2) , 465-472
循环炎症蛋白成纤维细胞生长因子21与骨质疏松以及骨折的关系研究
目的 系统性筛选循环炎症蛋白(circulating inflammatory proteins, CIPs)中影响骨质疏松症(osteoporosis, OP)和骨折的潜在靶点,通过临床样本验证其与骨密度(bone mineral density, BMD)的关联,为骨代谢调控提供新靶点证据。 方法 利用双向孟德尔随机化分析CIPs与OP和骨折的因果关系。纳入2型糖尿病(type 2 diabetes mellitus, T2DM)和健康人群,收集患者一般资料,检测并比较合并OP的T2DM组(DOP)、无OP的T2DM组(NDOP)及对照组的成纤维细胞生长因子21(fibroblast growth factor 21, FGF21)与骨代谢指标。 结果 EBI GWAS Catalog数据库中获取的共91种CIPs中,逆方差加权(inverse variance weighting, IVW)分析显示FGF21同时与OP和过去5年发生骨折存在潜在因果关系,其水平升高增加OP风险〔比值比(odds ratio, OR)=1.003,95%置信区间(confidence interval, CI):1.001~1.005;P=0.004〕和过去5年发生骨折风险(OR=1.004,95%CI:1.000~1.008;P=0.038),反向MR显示OP和过去5年发生骨折对正向分析中确定的FGF21在内的8种CIPs没有因果影响。临床研究显示:DOP组血浆FGF21〔396.92 (308.98,523.94) pg/mL〕高于NDOP组〔346.88(283.82,466.86) pg/mL〕和对照组〔233.66(169.95,327.78) pg/mL〕(均Pβ=-0.003,95%CI:-0.004~-0.002,P<0.0001)和全髋T值(β=-0.002,95%CI:-0.003~-0.001,P<0.0001)呈负相关,而在T2DM中,FGF21与腰椎(β=-0.003,95%CI:-0.004~-0.0014,P<0.0001)和全髋T值(β=-0.001,95%CI:-0.0022 ~-0.0005,P=0.002)呈负相关,调整上述协变量后,负相关同样存在。 结论 FGF21增加OP和过去5年发生骨折的风险,且存在因果关系,是T2DM骨骼健康受损的潜在危险因素。
- 20 March 2026
- Vol. 57 (2) , 465-472
Open Access循环炎症蛋白成纤维细胞生长因子21与骨质疏松以及骨折的关系研究
目的 系统性筛选循环炎症蛋白(circulating inflammatory proteins, CIPs)中影响骨质疏松症(osteoporosis, OP)和骨折的潜在靶点,通过临床样本验证其与骨密度(bone mineral density, BMD)的关联,为骨代谢调控提供新靶点证据。 方法 利用双向孟德尔随机化分析CIPs与OP和骨折的因果关系。纳入2型糖尿病(type 2 diabetes mellitus, T2DM)和健康人群,收集患者一般资料,检测并比较合并OP的T2DM组(DOP)、无OP的T2DM组(NDOP)及对照组的成纤维细胞生长因子21(fibroblast growth factor 21, FGF21)与骨代谢指标。 结果 EBI GWAS Catalog数据库中获取的共91种CIPs中,逆方差加权(inverse variance weighting, IVW)分析显示FGF21同时与OP和过去5年发生骨折存在潜在因果关系,其水平升高增加OP风险〔比值比(odds ratio, OR)=1.003,95%置信区间(confidence interval, CI):1.001~1.005;P=0.004〕和过去5年发生骨折风险(OR=1.004,95%CI:1.000~1.008;P=0.038),反向MR显示OP和过去5年发生骨折对正向分析中确定的FGF21在内的8种CIPs没有因果影响。临床研究显示:DOP组血浆FGF21〔396.92 (308.98,523.94) pg/mL〕高于NDOP组〔346.88(283.82,466.86) pg/mL〕和对照组〔233.66(169.95,327.78) pg/mL〕(均Pβ=-0.003,95%CI:-0.004~-0.002,P<0.0001)和全髋T值(β=-0.002,95%CI:-0.003~-0.001,P<0.0001)呈负相关,而在T2DM中,FGF21与腰椎(β=-0.003,95%CI:-0.004~-0.0014,P<0.0001)和全髋T值(β=-0.001,95%CI:-0.0022 ~-0.0005,P=0.002)呈负相关,调整上述协变量后,负相关同样存在。 结论 FGF21增加OP和过去5年发生骨折的风险,且存在因果关系,是T2DM骨骼健康受损的潜在危险因素。
- 16 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 774, 152042
ALKBH5 mediates FGF21 m6A demethylation in human bone marrow mesenchymal stem cells under high glucose conditions
- 16 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 774, 152042
ALKBH5 mediates FGF21 m6A demethylation in human bone marrow mesenchymal stem cells under high glucose conditions
- 13 August 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 1653-1663
Assessment of fracture risk in diabetic patients
Patients with diabetes often experience reduced bone strength, resulting in a higher fracture risk. This decline and increased susceptibility stem from intricate interactions within the bone microstructure. However, current gold standard methods for assessing bone strength, such as bone mineral density, and widely-used fracture risk assessment tools do not accurately predict fracture risk in diabetic patients. Therefore, it is crucial to incorporate additional indicators that evaluate bone quality and specific markers relevant to diabetes to enhance the accuracy of predictive models. Moreover, the selection of appropriate algorithms for model construction is essential. This review aims to introduce indicators from both imaging examinations and laboratory indicators that hold significant value for inclusion in fracture risk prediction models for diabetic patients. Additionally, this study provides an overview of the research progress in fracture risk prediction models for diabetic patients, serving as a valuable reference for clinical practice.
- 13 August 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 1653-1663
Assessment of fracture risk in diabetic patients
Patients with diabetes often experience reduced bone strength, resulting in a higher fracture risk. This decline and increased susceptibility stem from intricate interactions within the bone microstructure. However, current gold standard methods for assessing bone strength, such as bone mineral density, and widely-used fracture risk assessment tools do not accurately predict fracture risk in diabetic patients. Therefore, it is crucial to incorporate additional indicators that evaluate bone quality and specific markers relevant to diabetes to enhance the accuracy of predictive models. Moreover, the selection of appropriate algorithms for model construction is essential. This review aims to introduce indicators from both imaging examinations and laboratory indicators that hold significant value for inclusion in fracture risk prediction models for diabetic patients. Additionally, this study provides an overview of the research progress in fracture risk prediction models for diabetic patients, serving as a valuable reference for clinical practice.